Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, before U.S. markets open. The company will host a conference call and live webcast at 8:00 a.m. Eastern Time, with replay available on its website for at least 30 days.

News Market Reaction – RPRX

+3.94%

1 alert

+3.94% Session close to close

$24.68B Market Cap

0.7x Rel. Volume

In the Jul 16 session, RPRX gained 3.94%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This Q2 2026 results‑date announcement comes against a backdrop of low short positioning, as indicat...

Analysis

This Q2 2026 results‑date announcement comes against a backdrop of low short positioning, as indicated by a short‑interest signal categorized as low. Historically, earnings‑date headlines averaged a 0.58% move, so investors may focus more on the actual August 5 numbers than on this scheduling itself, while monitoring ongoing insider net selling as a potential overhang.

Key Figures

Earnings release date: August 5, 2026 Conference call time: 8:00 a.m. Eastern Time Replay availability: At least 30 days

3 metrics

Earnings release date August 5, 2026 Second quarter 2026 financial results reporting date

Conference call time 8:00 a.m. Eastern Time Start time for Q2 2026 results call on August 5, 2026

Replay availability At least 30 days Archived webcast duration on company website

Previous Earnings date Reports

2 past events · Latest: Apr 15 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 15	Earnings date notice	Negative	-0.5%	Scheduled Q1 2026 results and earnings call before market open.
Jan 20	Earnings date notice	Positive	+1.6%	Announced Q4 and full‑year 2025 results timing and conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past earnings date announcements have produced a modest average move of 0.58% with mixed positive and negative single‑day reactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com

FAQ

When will Royalty Pharma (RPRX) report its Q2 2026 earnings results?

Royalty Pharma will report its Q2 2026 financial results on Wednesday, August 5, 2026, before U.S. markets open. According to Royalty Pharma, the release will be accompanied by a conference call and webcast later that morning at 8:00 a.m. Eastern Time.

What time is Royalty Pharma's Q2 2026 earnings conference call on August 5, 2026?

Royalty Pharma's Q2 2026 earnings conference call is scheduled for 8:00 a.m. Eastern Time on August 5, 2026. According to Royalty Pharma, a simultaneous webcast will be available through the Investors section of the company’s website for live access.

How can investors access the Royalty Pharma (RPRX) Q2 2026 earnings webcast?

Investors can access the Q2 2026 earnings webcast by visiting the Investors > Events page on Royalty Pharma’s website. According to Royalty Pharma, this page provides conference call details, the live webcast link, and later an archived replay of the event.

Will there be a replay of Royalty Pharma's Q2 2026 earnings call for RPRX shareholders?

Yes, a replay of Royalty Pharma's Q2 2026 earnings call will be available on the company’s website. According to Royalty Pharma, the replay and webcast archive will remain accessible for at least 30 days after the event for investors’ review.

Where on Royalty Pharma’s website can I find details for the August 5, 2026 RPRX earnings call?

Details for the August 5, 2026 earnings call are available on the Investors page under Events on Royalty Pharma’s website. According to Royalty Pharma, this section provides call-in information and the live webcast and replay access links.